AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27415006 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CI-AKI and HLI
Number of subjects: 668
Study 27415585 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention targeting primary care physicians' and community pharmacists' attitudes and knowledge
Number of subjects: 0
Study 27415585 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27415618 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise program (PEP) including cycloergometry/kinesiotherapy plus nutritional therapy
Number of subjects: 29
Study 27415618 — intervention group
Group type: COMPARATOR
Intervention: Nutritional therapy (control)
Number of subjects: 29
Study 27416639 — intervention group
Group type: EXPERIMENTAL
Intervention: FocalyxDx (imaging)
Number of subjects: 300
Study 27416639 — intervention group
Group type: EXPERIMENTAL
Intervention: FocalyxBx (biopsy)
Number of subjects: 300
Study 27416639 — intervention group
Group type: EXPERIMENTAL
Intervention: FocalyxTx (treatment)
Number of subjects: 300
Study 27416639 — intervention group
Group type: EXPERIMENTAL
Intervention: Focalyx app (follow-up)
Number of subjects: 300
Study 27417011 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin assay
Number of subjects: 0
Study 27418050 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV dengue vaccine
Number of subjects: 3736
Study 27418050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3736
Study 27418324 — intervention group
Group type: EXPERIMENTAL
Intervention: ILR monitoring after AF ablation
Number of subjects: 57
Study 27418324 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring
Number of subjects: 57
Study 27418609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo stent
Number of subjects: 61
Study 27418632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 321
Study 27418632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 16 weeks
Number of subjects: 321
Study 27418632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin (12 or 16 weeks)
Number of subjects: 321
Study 27418632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin
Number of subjects: 321
Study 27418646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab, an anti-CCR4 monoclonal antibody
Number of subjects: 0
Study 27418929 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine suppression therapy (fixed dose)
Number of subjects: 14
Study 27418929 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age, sex, and BMI)
Number of subjects: 14
Study 27419080 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D
Number of subjects: 31
Study 27419080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 27420134 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Mania Rating Scale (YMRS)
Number of subjects: 3716
Study 27420134 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery-Asberg Depression Rating Scale (MADRS)
Number of subjects: 3716
Study 27420134 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scales (YMRS and MADRS)
Number of subjects: 3716
Study 27420361 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Tropheryma whipplei in different body sites
Number of subjects: 0
Study 27421052 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status disclosure among couples
Number of subjects: 194
Study 27421052 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive spouse dynamics in discordant relationships
Number of subjects: 194
Study 27421052 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of partners in testing
Number of subjects: 194
Study 27421053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile community health campaigns (CHCs)
Number of subjects: 334479
Study 27421053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile testing
Number of subjects: 334479
Study 27421053 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 334479
Study 27421053 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional masculine gender norms
Number of subjects: 334479
Study 27421056 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal ART intervention
Number of subjects: 3126
Study 27421618 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI subjects with above normal BMI (>25)
Number of subjects: 44
Study 27421618 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater physical activity in MCI subjects
Number of subjects: 44
Study 27421618 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier diet
Number of subjects: 44
Study 27421618 — intervention group
Group type: COMPARATOR
Intervention: Physical activity in subjects with subjective memory impairment
Number of subjects: 44
Study 27421763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic infrared thermography (DIRT)
Number of subjects: 25
Study 27421763 — intervention group
Group type: COMPARATOR
Intervention: CT angiography (CTA)
Number of subjects: 25
Study 27422011 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT intervention to improve staff communication
Number of subjects: 83
Study 27422011 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT intervention
Number of subjects: 83
Study 27422150 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment after 8 weeks of acute period treatment in MDD patients
Number of subjects: 1200
Study 27422150 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic test using questionnaire, neuropsychological assessment, and biomarkers in MDD patients
Number of subjects: 1200
Study 27422150 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal study over 96 weeks including 8-week acute treatment and 88-week stable treatment in MDD patients
Number of subjects: 1200
Study 27422279 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 15000
Study 27422279 — intervention group
Group type: COMPARATOR
Intervention: qHPV vaccine
Number of subjects: 15000
Study 27422301 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg bid
Number of subjects: 28
Study 27422301 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg bid
Number of subjects: 28
Study 27422301 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg bid (expansion cohort)
Number of subjects: 28
Study 27422301 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (all doses)
Number of subjects: 28
Study 27422342 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinfant series IgG concentration (age 7 months)
Number of subjects: 1754
Study 27422342 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG concentrations >0.61-5.58μg/mL
Number of subjects: 1754
Study 27422342 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG concentrations >2.48-17.69μg/mL
Number of subjects: 1754
Study 27422342 — intervention group
Group type: EXPERIMENTAL
Intervention: High IgG concentrations
Number of subjects: 1754
Study 27422342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 1754
Study 27422389 — intervention group
Group type: EXPERIMENTAL
Intervention: Value Pricing (VP) with adherence-contingent rebates (50% or 25% rebate based on adherence of at least 90% or 75%)
Number of subjects: 100
Study 27422389 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 100
Study 27423106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (target dose: 400mg/day by the end of titration) as adjunctive treatment to levetiracetam (LEV, stable dosage of >1000mg/day)
Number of subjects: 11
Study 27423106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (target dose: 400mg/day) as adjunctive treatment to levetiracetam (LEV, stable dosage of >1000mg/day)
Number of subjects: 11
Study 27423779 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg
Number of subjects: 33
Study 27423899 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β-1a biosimilar (various doses) via subcutaneous or intravenous injection in Trial A
Number of subjects: 24
Study 27423899 — intervention group
Group type: COMPARATOR
Intervention: Biosimilar with albumin, biosimilar without albumin, and a comparator (three different formulations) via intravenous injection followed by multiple subcutaneous injections in Trial B
Number of subjects: 24
Study 27427925 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STD risk-reduction intervention
Number of subjects: 521
Study 27428331 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir plus Peginterferon/Ribavirin (PR) for 12 weeks
Number of subjects: 163
Study 27428331 — intervention group
Group type: COMPARATOR
Intervention: Simeprevir plus Peginterferon/Ribavirin (PR) for >12 weeks
Number of subjects: 163
Study 27428331 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors associated with SVR12
Number of subjects: 163
Study 27428331 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 163
Study 27428331 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 163
Study 27428731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (1000 µg loading dose followed by 1000 µg daily infusion until discharge, max 21 days)
Number of subjects: 1089
Study 27428731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1089
Study 27428731 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin guidance
Number of subjects: 1089
Study 27428731 — intervention group
Group type: COMPARATOR
Intervention: No procalcitonin guidance
Number of subjects: 1089
Study 27429035 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
Number of subjects: 86
Study 27430242 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day) for 12 weeks
Number of subjects: 15
Study 27430417 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week program consisting of a reduced calorie diet, increased physical activity, and behavioral modification
Number of subjects: 72
Study 27430529 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMO care (pre-hospital thrombolysis with alteplase)
Number of subjects: 658
Study 27430529 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (in-hospital thrombolysis)
Number of subjects: 658
Study 27430529 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMO care
Number of subjects: 658
Study 27430708 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 69
Study 27430708 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 69
Study 27430981 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened casein-based extensively hydrolyzed formula (eHCF, Allernova AR®)
Number of subjects: 30
Study 27431598 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cardiac troponin-I (cTnI) measured at 24 hours after surgery
Number of subjects: 169
Study 27431598 — intervention group
Group type: EXPERIMENTAL
Intervention: Children undergoing surgery with cardiopulmonary bypass (CPB)
Number of subjects: 169
Study 27431598 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cTnI concentrations
Number of subjects: 169
Study 27431598 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI at 24 hours
Number of subjects: 169
Study 27431901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 3 measures of immune cell function (neutrophil CD88, monocyte HLA-DR, % regulatory T cells)
Number of subjects: 0
Study 27431901 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples from critically ill patients undergoing whole blood staining for immune cell surface markers
Number of subjects: 0
Study 27431901 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes include death from severe infection (sepsis) and change in organ failure
Number of subjects: 0
Study 27432417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 4675
Study 27432417 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 4675
Study 27432875 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 102
Study 27432917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/d
Number of subjects: 140
Study 27433419 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive lumbar interbody fusion (MILIF)
Number of subjects: 252
Study 27433488 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (MXR) 2,000 mg daily
Number of subjects: 69
Study 27433488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 27433488 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including MXR and placebo)
Number of subjects: 69
Study 27433840 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B protein
Number of subjects: 88
Study 27433840 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE)
Number of subjects: 88
Study 27433840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment at 21 days and 6 months post-surgery
Number of subjects: 88
Study 27433840 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B protein vs NSE
Number of subjects: 88
Study 27434039 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUITY X4 leads (Spiral Long, Spiral Short, or Straight)
Number of subjects: 764
Study 27435102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive delay (MDI <77)
Number of subjects: 0
Study 27435102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive delay with normal motor development
Number of subjects: 0
Study 27435102 — intervention group
Group type: COMPARATOR
Intervention: Psychomotor developmental index (PDI)
Number of subjects: 0
Study 27435145 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time sensor glucose (SG) for treatment decisions
Number of subjects: 10
Study 27435145 — intervention group
Group type: COMPARATOR
Intervention: Yellow Springs Instrument's (YSI) glucose analyzer
Number of subjects: 10
Study 27435396 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (AZD9291)
Number of subjects: 0
Study 27435396 — intervention group
Group type: COMPARATOR
Intervention: Rociletinib (CO-1686)
Number of subjects: 0
Study 27435453 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 73
Study 27435453 — intervention group
Group type: EXPERIMENTAL
Intervention: BsmI 'B' allele and TaqI 't' allele presence
Number of subjects: 73
Study 27435453 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 73
Study 27435882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP) for 1 year
Number of subjects: 157
Study 27436099 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg
Number of subjects: 16
Study 27436274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1441
Study 27436274 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes therapy
Number of subjects: 1441
Study 27436274 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 1441
Study 27436274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid measurements
Number of subjects: 1441
Study 27436285 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stress-dose steroids
Number of subjects: 0
Study 27436285 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27436749 — intervention group
Group type: COMPARATOR
Intervention: MJ-related cues
Number of subjects: 33
Study 27436871 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 Left Ventricular Assist System (LVAS)
Number of subjects: 50
Study 27436878 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography-guided beating-heart mitral valve repair with expanded polytetrafluoroethylene cordal insertion (Harpoon TSD-5)
Number of subjects: 11
Study 27436882 — intervention group
Group type: EXPERIMENTAL
Intervention: AngelMed Guardian System
Number of subjects: 0
Study 27437054 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneInsight Clinic (GIC) implementation
Number of subjects: 8
Study 27437054 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneInsight Clinic (GIC)
Number of subjects: 8
Study 27438106 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with AF
Number of subjects: 10135
Study 27438353 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO levels
Number of subjects: 70
Study 27438353 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO levels of 31 ppb
Number of subjects: 70
Study 27438353 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO levels of 0-20 ppb
Number of subjects: 70
Study 27438353 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO levels of 21-40 ppb
Number of subjects: 70
Study 27438569 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Program (quitters)
Number of subjects: 33
Study 27438569 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 33
Study 27438938 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial pain location, severity, and interference scores measured using the Brief Pain Inventory Short Form.
Number of subjects: 83
Study 27438938 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial pain location in CRS patients.
Number of subjects: 83
Study 27439593 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week supervised exercise program
Number of subjects: 10
Study 27439618 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET) during a ten-week inpatient program
Number of subjects: 11
Study 27439667 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' health beliefs about lifestyle habits
Number of subjects: 22
Study 27439667 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouses' health beliefs about lifestyle habits
Number of subjects: 22
Study 27439667 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' beliefs regarding supervised exercise
Number of subjects: 22
Study 27439667 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' beliefs regarding medication
Number of subjects: 22
Study 27439667 — intervention group
Group type: EXPERIMENTAL
Intervention: General agreement between patients and spouses
Number of subjects: 22
Study 27439710 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Sentrino(®) CGM system
Number of subjects: 20
Study 27440251 — intervention group
Group type: EXPERIMENTAL
Intervention: Comoestas group (electronic diary with alert system and facilitated communication)
Number of subjects: 663
Study 27440251 — intervention group
Group type: COMPARATOR
Intervention: Classic group (paper headache diary)
Number of subjects: 663
Study 27440251 — intervention group
Group type: EXPERIMENTAL
Intervention: Comoestas group
Number of subjects: 663
Study 27440251 — intervention group
Group type: COMPARATOR
Intervention: Classic group
Number of subjects: 663
Study 27440259 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g LNS-PL/d (118 kcal) containing essential fatty acids and vitamins and minerals until delivery
Number of subjects: 4011
Study 27440259 — intervention group
Group type: COMPARATOR
Intervention: 60 mg Fe + 400 μg folic acid/d
Number of subjects: 4011
Study 27440260 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (Whey-35)
Number of subjects: 60
Study 27440260 — intervention group
Group type: EXPERIMENTAL
Intervention: Micellar casein (MCas-35)
Number of subjects: 60
Study 27440260 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat protein hydrolysate (WPH-60)
Number of subjects: 60
Study 27440260 — intervention group
Group type: COMPARATOR
Intervention: Wheat protein (WPH-35)
Number of subjects: 60
Study 27440628 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative heart rate >96 beats min(-1)
Number of subjects: 15087
Study 27440628 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative heart rate <60 beats min(-1)
Number of subjects: 15087
Study 27440628 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined binary heart rate thresholds
Number of subjects: 15087
Study 27440630 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert stroke incidence after non-cardiac surgery
Number of subjects: 100
Study 27440630 — intervention group
Group type: EXPERIMENTAL
Intervention: Major general surgery
Number of subjects: 100
Study 27440630 — intervention group
Group type: EXPERIMENTAL
Intervention: Major orthopaedic surgery
Number of subjects: 100
Study 27440630 — intervention group
Group type: EXPERIMENTAL
Intervention: Major urological or gynaecological surgery
Number of subjects: 100
Study 27440630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk surgery
Number of subjects: 100
Study 27440637 — intervention group
Group type: EXPERIMENTAL
Intervention: Long mean distribution time (MDT) and high end-inspiratory flow (EIF)
Number of subjects: 8
Study 27440637 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of inspiratory time (TI) from 33% to 15% and postinspiratory pause (TP) from 10% to 28%
Number of subjects: 8
Study 27440637 — intervention group
Group type: COMPARATOR
Intervention: Heat and moisture exchanger
Number of subjects: 8
Study 27440658 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-administered physical therapy (10 minutes twice a day for 3 weeks from 34 to 36 weeks' PMA)
Number of subjects: 153
Study 27440658 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 153
Study 27441182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Disc Arthroplasty (CDA) with Prestige LP Disc
Number of subjects: 280
Study 27441182 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 280
Study 27441182 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA
Number of subjects: 280
Study 27441182 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 280
Study 27441564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0
Study 27441564 — intervention group
Group type: COMPARATOR
Intervention: Control details not available
Number of subjects: 0
Study 27442600 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 40 mg/m², lenalidomide, low-dose dexamethasone
Number of subjects: 15